States crimp Zyprexa access: Medicaid restrictions cutting into sales of Lilly’s top drug
Eli Lilly and Co.’s top seller Zyprexa, pummeled in recent quarters by concerns over side effects, now faces a growing challenge from some of its biggest customers: state Medicaid programs. Citing high costs, more than a half dozen states have moved Zyprexa and other pricey anti-psychotics off preferred drug lists or made it harder for doctors to prescribe them for patients on Medicaid, the state-federal program that provides health care coverage for the poor and disabled. Georgia, for instance, saved…